diaDexus licenses prostate test to SmithKline Beecham
This article was originally published in Clinica
SmithKline Beecham's clinical laboratories division (SBCL) has obtained the exclusive rights from diaDexus to use and further improve a blood test that measures stages of development of prostate cancer. The test, called PLA2, is the first product developed and licensed by diaDexus, a Santa Clara, California-based joint venture formed in 1997 by SmithKline Beecham and Incyte Pharmaceuticals (Clinica No 773, p 9).
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.